© Reuters.
COMPASS Pathways plc (NASDAQ:CMPS), a pharmaceutical company specializing in the development of psychedelic-based therapies, has seen a significant transaction from one of its directors. George Jay Goldsmith, who also holds a more than ten percent ownership stake in the company, has sold a substantial number of ordinary shares.
According to recent filings, Goldsmith executed multiple sales of COMPASS Pathways shares on March 12 and March 13. On the first day, he sold 15,740 shares at a weighted average price of $10.5803, and on the following day, another 17,203 shares were sold at an average of $10.8049 per share. The transactions were carried out in multiple tranches within a price range of $10.36 to $11.07. These sales have resulted in a total transaction value of approximately $704,821.
It is noteworthy that these sales were executed automatically under a Rule 10b5-1 trading plan, which had been previously adopted by Goldsmith. This type of trading plan allows company insiders to sell shares at predetermined times to avoid accusations of insider trading.
The shares sold by Goldsmith are reported to be direct holdings, while an equivalent number of shares were sold indirectly by his spouse, Dr. Ekaterina Malievskaia. Despite the marital relationship and the joint trading plan, both parties have disclaimed beneficial ownership of each other’s shares in the issuer.
Following these transactions, Goldsmith’s direct ownership in COMPASS Pathways stands at 4,069,630 shares, reflecting his continued significant stake in the company. The sales represent a fraction of his overall holding, indicating that while taking some profits, Goldsmith remains heavily invested in COMPASS Pathways’ future.
Investors often watch insider transactions for insights into how company executives and directors view the stock’s valuation and prospects. In this case, the automated nature of the sales under a pre-established trading plan may suggest that the transactions were not based on any recent assessment of the company’s performance or outlook.
COMPASS Pathways continues to be a key player in the burgeoning field of psychedelic medicine, with ongoing research into the therapeutic potential of psilocybin and other compounds for mental health conditions. Investors will undoubtedly continue to monitor insider activity for further indications of the company’s trajectory.
InvestingPro Insights
COMPASS Pathways plc (NASDAQ:CMPS) has been navigating a volatile market, reflected in the company’s recent stock performance and financial metrics. An InvestingPro Tips analysis reveals that the company’s stock has taken a considerable hit over the last week with a price total return of -9.97%. This downward trend is contrasted by a strong return over the last three months, where the stock has seen a price total return of 22.44%. These fluctuations underscore the company’s volatile stock price movements and could be a point of interest for investors looking at the short-term performance.
On the financial front, COMPASS Pathways holds more cash than debt on its balance sheet, which can be a reassuring sign for investors concerned about the company’s solvency. However, the company is quickly burning through cash, with an operating income of approximately -$124.04 million over the last twelve months as of Q4 2023. This cash burn rate, coupled with weak gross profit margins, suggests that careful financial management will be crucial for the company moving forward.
Another critical point for potential investors is that analysts do not anticipate the company will be profitable this year, which is reflected in the negative P/E ratio (adjusted) of -5.31. Despite these challenges, COMPASS Pathways’ liquid assets exceed its short-term obligations, providing some level of financial stability in the near term.
For those interested in more in-depth analysis, InvestingPro offers additional insights on COMPASS Pathways. There are 10 additional InvestingPro Tips available, which can be accessed through the dedicated InvestingPro page for COMPASS Pathways at https://www.investing.com/pro/CMPS. To get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, readers can use the coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
